Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26131525 | 1.00 | OPRK1 (0.43) | OPRK1JAK2JAK1TRPV1JAK3 | |
| SCHEMBL26590381 | 0.93 | OPRK1 (0.47) | OPRK1EGFR | |
| SCHEMBL21513454 | 0.91 | OPRK1 (0.36) | OPRK1JAK2JAK1TRPV1EGFR | |
| SCHEMBL21512822 | 0.84 | OPRK1 (0.45) | OPRK1JAK2EGFR | |
| SCHEMBL29969052 | 0.84 | OPRK1 (0.45) | OPRK1JAK2EGFR | |
| SCHEMBL29969465 | 0.83 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL21512940 | 0.83 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL29968751 | 0.83 | JAK2 (0.37) | OPRK1JAK2EGFR | |
| SCHEMBL29969876 | 0.82 | OPRK1 (0.47) | OPRK1TRPV1 | |
| SCHEMBL26132379 | 0.82 | OPRK1 (0.47) | OPRK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | OPRK1 3281/4885JAK2 925/4885JAK1 1427/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | OPRK1 3281/4885JAK2 925/4885JAK1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.